J&J’s Imaavy nears FDA approval on positive blood-disorder data

Johnson & Johnson (NYSE:JNJ) reported positive data from a late-stage clinical trial for its drug Imaavy, strengthening its bid to secure the first regulatory approval for a rare, life-threatening autoimmune blood disorder.

The New Brunswick, New Jersey-based healthcare giant presented data from the Phase 2/3 ENERGY study at a medical congress in Stockholm, evaluating the therapy in adults with warm autoimmune hemolytic anemia.

The condition causes the immune system to mistakenly destroy its own red blood cells, leading to severe anemia, fatigue, and potential organ failure.

There are currently no therapies approved by the U.S. Food and Drug Administration for the disease.

In the trial involving 115 adult patients, a 30 milligram-per-kilogram dose of Imaavy met the primary goal by achieving a statistically significant durable hemoglobin response.

The treatment group produced approximately three times more responders than the placebo cohort by the 24th week of the study.

Data showed a rapid onset of action, with mean hemoglobin levels rising by 1 gram per deciliter or more within the first week of treatment.

By Week 24, nearly two-thirds of the evaluated patients met stringent target thresholds, defined as reaching an overall hemoglobin concentration of at least 10 grams per deciliter alongside an increase from baseline of at least 2 grams per deciliter without requiring rescue therapy.

Beyond blood counts, patients receiving Imaavy reported sustained improvements in chronic fatigue scales.

The treatment also allowed for a reduction in standard-of-care steroid dependence; patients tracking the drug achieved a 15% mean reduction in corticosteroid doses compared to a 4% reduction in the placebo arm.

The safety profile observed during the 24-week evaluation was consistent with previous clinical trials for Imaavy, which is already FDA-approved for generalized myasthenia gravis—another antibody-driven autoimmune condition.

The most frequent side effects included peripheral edema, diarrhea, and fever.

The clinical findings support J&J’s supplemental Biologics License Application, which was granted Priority Review status by the FDA.

The regulatory designation expedites the evaluation timeline for drugs that offer significant potential improvements over existing care options for serious conditions.

J&J's push into the rare autoantibody market is part of a broader pharmaceutical strategy targeting FcRn inhibitors, a fast-growing class of immunology drugs designed to filter out disease-causing proteins from circulation.